[{"address1": "5505 Morehouse Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 267 4467", "website": "https://www.artivabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.", "fullTimeEmployees": 82, "companyOfficers": [{"maxAge": 1, "name": "Dr. Fred  Aslan M.D.", "age": 49, "title": "President, CEO & Director", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 917304, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  Flynn Ph.D.", "age": 50, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 499368, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer Kinsbruner Bush Esq., J.D.", "age": 49, "title": "Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 630312, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Neha  Krishnamohan", "age": 37, "title": "CFO & Executive VP of Corporate Development", "yearBorn": 1987, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thorsten  Graef M.D., Ph.D.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Heather  Raymon Ph.D.", "age": 60, "title": "Senior Vice President of Research & Early Development", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Moriarty Ph.D.", "title": "Senior VP of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.01, "open": 3.99, "dayLow": 3.99, "dayHigh": 4.57, "regularMarketPreviousClose": 4.01, "regularMarketOpen": 3.99, "regularMarketDayLow": 3.99, "regularMarketDayHigh": 4.57, "forwardPE": -1.7011495, "volume": 49894, "regularMarketVolume": 49894, "averageVolume": 69298, "averageVolume10days": 98190, "averageDailyVolume10Day": 98190, "bid": 4.36, "ask": 4.5, "bidSize": 100, "askSize": 100, "marketCap": 107844496, "fiftyTwoWeekLow": 3.37, "fiftyTwoWeekHigh": 17.31, "priceToSalesTrailing12Months": 41.462704, "fiftyDayAverage": 8.4494, "twoHundredDayAverage": 10.749549, "currency": "USD", "enterpriseValue": -23818384, "floatShares": 4323015, "sharesOutstanding": 24289300, "sharesShort": 1167703, "sharesShortPriorMonth": 1168808, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0481, "heldPercentInsiders": 0.20643, "heldPercentInstitutions": 0.91093004, "shortRatio": 15.66, "shortPercentOfFloat": 0.0484, "impliedSharesOutstanding": 24553300, "bookValue": 8.276, "priceToBook": 0.53649104, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -61276000, "trailingEps": -2.48, "forwardEps": -3.45, "enterpriseToRevenue": -9.157, "enterpriseToEbitda": 0.407, "52WeekChange": -0.66583335, "SandP52WeekChange": 0.22903383, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ARTV", "underlyingSymbol": "ARTV", "shortName": "Artiva Biotherapeutics, Inc.", "longName": "Artiva Biotherapeutics, Inc.", "firstTradeDateEpochUtc": 1721395800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "8e252093-be09-3198-b7f1-62334b202526", "messageBoardId": "finmb_672643147", "gmtOffSetMilliseconds": -18000000, "currentPrice": 4.44, "targetHighPrice": 23.0, "targetLowPrice": 18.0, "targetMeanPrice": 21.0, "targetMedianPrice": 21.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 146631008, "totalCashPerShare": 6.037, "ebitda": -58574000, "totalDebt": 14968000, "quickRatio": 11.137, "currentRatio": 11.327, "totalRevenue": 2601000, "debtToEquity": 7.447, "revenuePerShare": 0.485, "grossProfits": 2601000, "operatingCashflow": -51057000, "grossMargins": 1.0, "operatingMargins": -23.44675, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]